The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. RESULTS: A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], -0.46 [95% CI, -0.80 to -0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. CONCLUSIONS AND RELEVANCE: There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medical uses of THC-based cannabinoids are associated with an increased risk of short-term adverse effects, but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, data analysis using SMD allowed the inclusion of a large variety of measurements in the evaluation of the outcomes and allowed us to include many more RCTs for all relevant medical indications than in a previous extensive meta-analysis [3].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that efforts to selfmanage depression with cannabis are increasing [71][72][73][74][75] (also Aaron L. Sarvet, MPH, written communication, January 2, 2018) despite lack of evidence that cannabinoids are effective for this purpose 76,77 ; prospectively, cannabis worsens the course of depressive disorders.78”
From Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States (2018) · cites this paper as [75]
In the citing paper
“Several clinical studies have demonstrated the analgesic effects of cannabinoids in human disease states, including pain associated with diabetes, chemotherapy, multiple sclerosis, and fibromyalgia (Lynch and Ware, 2015;Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“A comprehensive meta-analysis shows that medicinal cannabis and cannabinoids effectively alleviate different types of pain, such as neuropathic, fibromyalgia, multiple sclerosis, cancer, diabetic neuropathy, refractory pain due to multiple sclerosis or other neurological conditions, rheumatoid arthritis, noncancer pain, central pain, musculoskeletal problems, and chemotherapy-induced pain (Whiting”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“Although several studies show that 'medical cannabis' can improve various types of pain, cannabimimetic side effects, which include drowsiness or fatigue, dizziness, dry mouth, nausea, and cognitive effects, have also been reported (Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,461
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Research works printed but not linked: 20
- [8]8. Canadian Agency for Drugs and Technologies in Health. CADTH Peer Review Checklist for Search Strategies (Internet). Ottawa, Canada: CADTH; 2013. https://www.cadth.ca/resources/finding-evidence /cadth-peer-review-checklist-search-strategies. Accessed March 17, 2014.
- [14]14. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
- [16]16. Hagenbach U, Luz S, Brenneisen R, Mäder M. The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury. Paper presented at: IACM 2nd Conference on Cannabinoids in Medicine; September 12-13, 2003; Cologne, Germany.
- [18]18. Denver, CO. Am J Respir Crit Care Med. 2011;183(1):A2720.
- [46]46. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50 (4):636-645.
- [48]48. Harden-Harrison MM, Munsell MF, Fisch MJ, et al. Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. Paper presented at: International MASCC/ISOO Symposium: Supportive Care in Cancer; June 28-30, 2012; New York, NY. Support Care Cancer. 2012;20:S209-S210.
- [50]50. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1989;8:326.
- [52]52. Chan HS, MacLeod SM, Correia JA. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
- [54]54. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9-tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
- [56]56. McCabe M, Smith FP, Goldberg D, et al. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting. Proc Am Assoc Cancer Res and Am Soc Clin Oncol. 1981;22:416.
- [63]63. Ware M, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Paper presented at: Canadian Rheumatology Association Meeting; February 18-21, 2009; Kananaskis, AB: Canada. Abstract 149 J Rheumatol. 2009;36(11):2607.
- [80]80. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- [90]90. Abrams DI, Jay CA, Vizoso H, et al. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: results of a randomized, placebo-controlled clinical trial. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
- [116]116. Cambridge Laboratories Ltd. A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. metaRegister of Controlled Trials. http://isrctn.org /ISRCTN15330757. Accessed April 7, 2014.
- [136]136. Zajicek J, Reif M, Schnelle M; UK MUSEC Study Investigators. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis -results of the MUSEC study. Paper presented at: IACM 5th Conference on Cannabinoids in Medicine; October 2-3, 2009; Cologne, Germany. 137.
- [93]93. Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. Paper presented at: 22nd Congress of the ECTRIMS; September 27-30, 2006; Madrid, Spain. 138. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands. 139. Center for Medicinal Cannabis Research. Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00248378. Accessed April 7, 2014. 140. Institut fur Klinische Forschung Germany;
- [155]155. Rohleder C, Pahlisch F, Schaefer C, et al. The endocannabinoid system as a pharmacological target for antipsychotic treatment and more? Paper presented at: 8th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco, CA. Early Interv Psychiatry. 2012;6(suppl 1):7 doi:10.1111/j.1751-7893 .2012.00392.x. · DOI
- [164]164. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. MeDRA (Medical Dictionary for Regulatory Activities). http://www .meddra.org/. Accessed September 2, 2014.
- [178]178. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids as Co-Analgesics: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health;2010.
- [179]179. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health);2010.
Cited by
Sorted by citations
Items 801–900 of 1,002
Understanding the basics of cannabidiol from cannabis to apply to therapeutics in epilepsy
Hay, L. (2020) · South African Medical Journal · doi:10.7196/samj.2020.v110i2.14410 · Cited by 18
Knowledge about and attitudes towards medical cannabis among Austrian university students
Felnhofer, A., Kothgassner, O. D., Stoll, A., & Klier, C. M. (2021) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2021.102700 · Cited by 18
Ng, J. Y., Abrams, A., Pathak, A., Tahir, U., & Jomy, J. (2021) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2021.102098 · Cited by 18
A critical review of cannabis in medicine and dentistry: A look back and the path forward
Abidi, A. H., Alghamdi, S. S., & Derefinko, K. J. (2022) · Clinical and Experimental Dental Research · doi:10.1002/cre2.564 · Cited by 22
Cannabis and sleep disorders: not ready for prime time? A qualitative scoping review
Amaral, C., Gonzaga, C. C., Scaranelo, A. M., Chapman, K. R., Chatkin, J. M., & Ferreira, I. M. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10428 · Cited by 19
Pain Management and Work Capacity: Evidence From Workers’ Compensation and Marijuana Legalization
Abouk, R., Ghimire, K., Maclean, J. C., & Powell, D. (2023) · Journal of Policy Analysis and Management · doi:10.1002/pam.22479 · Cited by 19
Livne, O., Malte, C. A., Olfson, M., Wall, M. M., Keyes, K. M., Maynard, C. C., Gradus, J. L., Saxon, A. J., Martins, S. S., Keyhani, S., et al. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230168 · Cited by 19
Wirksamkeit und Sicherheit von Cannabisarzneimitteln: Ergebnisse der CaPRis-Studie
CaPRis-Projektgruppe, Hoch, E., Friemel, C. M., Schneider, M., Pogarell, O. M., Hasan, A., & Preuss, U. W. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02965-3 · Cited by 18
Alkabbani, W., Marrie, R. A., Bugden, S., Alessi‐Severini, S., Bolton, J. M., Daeninck, P. J., & Leong, C. (2019) · Addiction · doi:10.1111/add.14719 · Cited by 20
Zeiger, J. S., Silvers, W. S., Fleegler, E. M., & Zeiger, R. S. (2019) · Journal of Cannabis Research · doi:10.1186/s42238-019-0006-9 · Cited by 18
Cannabis-based medicines for chronic pain management
Sharon, H., & Brill, S. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000775 · Cited by 18
Medical Cannabis for the Primary Care Physician
Slawek, D. E., Meenrajan, S. R., Alois, M., Barker, P. C., Estores, I. M., & Cook, R. L. (2019) · Journal of Primary Care & Community Health · doi:10.1177/2150132719884838 · Cited by 19
Who is asking about medicinal cannabis in palliative care?
Panozzo, S., Le, B. H. C., Collins, A., Weil, J., Whyte, J., Barton, M. B., Coperchini, M., Rametta, M., & Philip, J. A. M. (2020) · Internal Medicine Journal · doi:10.1111/imj.14732 · Cited by 18
Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions
Woo, J., van Reekum, E. A., Rosic, T., & Samaan, Z. (2020) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s254264 · Cited by 18
Diorio, C. J., Kelly, K. M., Afungchwi, G. M., Ladas, E. J., & Marjerrison, S. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28324 · Cited by 18
Croker, J. A., Bobitt, J., Arora, K., & Kaskie, B. P. (2020) · Clinical Gerontologist · doi:10.1080/07317115.2020.1797971 · Cited by 18
Understanding Cannabis-Based Therapeutics in Sports Medicine
Maurer, G., Mathews, N. M., Schleich, K. T., Slayman, T. G., & Marcussen, B. L. (2020) · Sports Health A Multidisciplinary Approach · doi:10.1177/1941738120956604 · Cited by 20
Medical cannabis and cognitive performance in middle to old adults treated for chronic pain
Sznitman, S. R., Vulfsons, S., Meiri, D., & Weinstein, G. (2020) · Drug and Alcohol Review · doi:10.1111/dar.13171 · Cited by 18
Personnel training and patient education in medical marijuana dispensaries in Oregon
Linares, R., Choi‐Nurvitadhi, J., Cooper, S., Ham, Y., Ishmael, J. E., & Zweber, A. (2016) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2015.12.015 · Cited by 18
Sideris, A., Piskoun, B., Russo, L., Norcini, M., Blanck, T. J. J., & Recio‐Pinto, E. (2016) · Molecular Pain · doi:10.1177/1744806916649191 · Cited by 18
The Cream of the Crop: Biology, Breeding, and Applications ofCannabis Sativa
Schilling, S., Dowling, C. A., Shi, J., Ryan, L., Hunt, D. J. L., O’Reilly, E., Perry, A. S., Kinnane, O., McCabe, P. F., & Melzer, R. (2021) · Wiley eBooks · doi:10.1002/9781119312994.apr0740 · Cited by 48
Mathur, K., Vuppalanchi, V., Gelow, K., Vuppalanchi, R., & Lammert, C. S. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05756-7 · Cited by 17
Buchwald, D., Brønnum, D., Melgaard, D., & Leutscher, P. D. C. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0298 · Cited by 17
Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease
Argueta, D. A., Aich, A., Muqolli, F., Cherukury, H. M., Sagi, V., DiPatrizio, N. V., & Gupta, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123902 · Cited by 17
Cannabis for medical purposes: A cross-sectional analysis of health care professionals' knowledge
Rice, J., Hildebrand, A. D., Waslo, C. S., Cameron, M. H., & Jones, K. D. (2021) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000590 · Cited by 18
Impact of pre-operative recreational marijuana use on outcomes two years after orthopaedic surgery
Albelo, F., Baker, M., Zhang, T., Schneider, M. B., Jauregui, J. J., Nadarajah, V., Meredith, S. J., Packer, J. D., & Henn, R. F. (2021) · International Orthopaedics · doi:10.1007/s00264-021-05069-3 · Cited by 17
Medical cannabis authorization and the risk of cardiovascular events: a longitudinal cohort study
Zongo, A., Lee, C., Dyck, J. R. B., El-Mourad, J., Hyshka, E., Hanlon, J. G., & Eurich, D. T. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02229-6 · Cited by 17
Enkema, M. C., Hasin, D. S., Browne, K. C., Stohl, M., Shmulewitz, D., Fink, D. S., Olfson, M., Martins, S. S., Bohnert, K. M., Sherman, S. E., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000002345 · Cited by 17
Medical marijuana utilization in gynecologic cancer patients
Fehniger, J., Brodsky, A. L., Kim, A., & Pothuri, B. (2021) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2021.100820 · Cited by 16
Gahr, M., Ziller, J., Keller, F., Muche, R., Preuss, U. W., & Schönfeldt‐Lecuona, C. (2021) · European Journal of Public Health · doi:10.1093/eurpub/ckab207 · Cited by 17
Goodman, S. E., Leos‐Toro, C., & Hammond, D. G. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2021.2023186 · Cited by 17
Impact of Cannabinoid Compounds on Skin Cancer
Ramer, R., Wendt, F., Wittig, F., Schäfer, M., Boeckmann, L., Emmert, S., & Hinz, B. (2022) · Cancers · doi:10.3390/cancers14071769 · Cited by 20
Substance-Related and Addictive Disorders
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890425787.x16_substance_related_disorders · Cited by 25
Oikonomou, P., & Jost, W. H. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02529-x · Cited by 17
Impact of prenatal cannabis exposure on functional connectivity of the salience network in children
Faraj, M. M., Evanski, J. M., Zundel, C. G., Peters, C. A., Brummelte, S., Lundahl, L. H., & Marusak, H. A. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25136 · Cited by 17
Brkljača, N., Đurović, S. D., Milošević, S., Gašić, U. M., Panković, D. M., Zeković, Z. P., & Pavlić, B. (2023) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2023.101213 · Cited by 17
Medical cannabis: What practitioners need to know
van Rensburg, R., Lorente, V. P.-F., Blockman, M., Moodley, K., Wilmshurst, J. M., & Decloedt, E. H. (2020) · South African Medical Journal · doi:10.7196/samj.2020.v110i3.14403 · Cited by 18
Rossi, G. N., Osório, F. D. L., Morgan, C. J. A., Crippa, J. A. S., Bouso, J. C., Rocha, J. M., Zuardi, A. W., Hallak, J. E. C., & SANTOS, R. G. D. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.07.034 · Cited by 17
Marijuana use among cancer survivors: Quantifying prevalence and identifying predictors
Poghosyan, H., & Poghosyan, A. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106634 · Cited by 18
Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression
Wiese, B. M., Liktor‐Busa, E., Levine, A. A., Couture, S. A., Nikas, S. P., Ji, L., Liu, Y., Mackie, K., Makriyannis, A., Largent‐Milnes, T. M., et al. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0076 · Cited by 17
Keethakumar, A., Mehra, V. M., Khanlou, N., & Tamim, H. (2021) · BMC Public Health · doi:10.1186/s12889-020-10074-z · Cited by 17
Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network
Zeiger, J. S., Silvers, W. S., Winders, T. A., Hart, M., & Zeiger, R. S. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.01.014 · Cited by 17
Maher, D. P., Carr, D. B., Hill, K. P., McGeeney, B. E., Weed, V. F., Jackson, W., DiBenedetto, D. J., Moriarty, E. M., & Kulich, R. J. (2017) · Pain Medicine · doi:10.1093/pm/pnx143 · Cited by 16
Non-medical and illicit use of psychoactive drugs
Schenk, S., Bruno, R., & Nielsen, S. (2017) · Current topics in behavioral neurosciences · doi:10.1007/978-3-319-60016-1 · Cited by 17
Singh, D., & Lippmann, S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1413281 · Cited by 17
The Void in Clinician Counseling of Cannabis Use
Calcaterra, S. L., Cunningham, C. O., & Hopfer, C. J. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05612-4 · Cited by 16
Sexton, T. R., & Alshaarawy, O. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108035 · Cited by 16
(Endo)Cannabinoids and Gynaecological Cancers
Taylor, A. H., Tortolani, D., Ayakannu, T., Konje, J. C., & Maccarrone, M. (2020) · Cancers · doi:10.3390/cancers13010037 · Cited by 16
Brucki, S. M. D., Adoni, T., de Almeida, C. M. O., de Andrade, D. C., Anghinah, R., BARBOSA, L. M., Bazán, R., Carvalho, A. A. D. S., CARVALHO, W., Christo, P. P., et al. (2021) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2020-0432 · Cited by 18
Sabmeethavorn, Q. W., Bonomo, Y. A., & Hallinan, C. M. (2022) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riac005 · Cited by 16
Supercritical fluids in analysis of cannabinoids in various Cannabis products
Pilařová, V., Hadysová, Z., Švec, F., & Nováková, L. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.340452 · Cited by 17
Key Factors that Influence Consumer Preferences for Natural‐Hyped Products
Velasco, F., Cardenas, M., Cardenas, J. J., & Martin, S. L. (2022) · Psychology and Marketing · doi:10.1002/mar.21730 · Cited by 16
Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients
Ajrawat, P., Yang, Y., Wasilewski, E., Leroux, T. S., Ladha, K. S., Bhatia, A., Singh, M., Thaker, S., Kapoor, M., Furlan, A. D., et al. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0143 · Cited by 16
Modaresi, F., & Talachian, K. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-022-00447-7 · Cited by 16
Rouzer, S. K., Gutiérrez, J., Larin, K. V., & Miranda, R. C. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114318 · Cited by 16
Understanding the relationship between social media use and depression: a review of the literature
Zhu, W., Mou, J., Benyoucef, M., Kim, J., Hong, T., & Chen, S. (2023) · Online Information Review · doi:10.1108/oir-04-2021-0211 · Cited by 17
Lapteva, M., Barros, J. F., & Kalia, Y. N. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020202 · Cited by 16
Elucidating the Mechanism of Metabolism of Cannabichromene by Human Cytochrome P450s
Roy, P., Maturano, J., Hasdemir, H. S., Lopez, A. F., Xu, F., Hellman, J., Tajkhorshid, E., Šarlah, D., & Das, A. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00336 · Cited by 17
Review of the Use of Medicinal Cannabis Products in Palliative Care
Troyer, J., & Tanco, K. C. (2024) · Cancers · doi:10.3390/cancers16071412 · Cited by 17
Medicinal Use of Different Cannabis Strains: Results from a Large Prospective Survey in Germany
Szejko, N., Becher, E., Heimann, F., Grotenhermen, F., & Müller‐Vahl, K. (2024) · Pharmacopsychiatry · doi:10.1055/a-2261-2269 · Cited by 16
Kales, H. C. (2015) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.10.001 · Cited by 15
Cannabinoid Receptor Type 1 in the Brain Regulates the Affective Component of Visceral Pain in Mice
Bajic, D., Monory, K., Conrad, A., Maul, C., Schmid, R. M., Wotjak, C. T., & Stein‐Thoeringer, C. K. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.05.041 · Cited by 18
Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain
Casey, S. L., & Vaughan, C. W. (2018) · Medicines · doi:10.3390/medicines5030067 · Cited by 19
Ferguson, E. G., Mannes, Z. L., & Ennis, N. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.021 · Cited by 17
Cannabis Use and Cognition in Adults Prescribed Opioids for Persistent Pain
Wildes, M., Bigand, T. L., Layton, M. E., & Wilson, M. (2019) · Pain Management Nursing · doi:10.1016/j.pmn.2019.06.014 · Cited by 17
Hegazy, O., & Platnick, H. (2019) · Cureus · doi:10.7759/cureus.6312 · Cited by 16
Efron, D., Taylor, K., Payne, J. M., Freeman, J. L., Cranswick, N., Mulraney, M., Prakash, C., Lee, K. J., & Williams, K. J. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034362 · Cited by 18
Cannabinoids use in adolescents and young adults with cancer: a single-center survey
Podda, M. G., Bagliacca, E. P., Sironi, G., Veneroni, L., Silva, M., Angi, M., Massimino, M., Ferrari, A., & Clerici, C. A. (2020) · Tumori Journal · doi:10.1177/0300891620912022 · Cited by 16
Quantitative analysis of cannabinoids using benchtop NMR instruments
Araneda, J. F., Chu, T., Leclerc, M. C., Riegel, S. D., & Spingarn, N. E. (2020) · Analytical Methods · doi:10.1039/d0ay01511c · Cited by 16
A review of cannabidiol‐containing electronic liquids—Current regulations and labelling accuracy
Dunn, K., Taylor, A., & Turfus, S. C. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3102 · Cited by 16
Moreno‐Sanz, G., Madiedo, A., Hernández, P., Kratz, J. W., Aizpurua‐Olaizola, O., Brown, M. R. D., Lopez, J., Patiño, J., & Mendivelso, F. O. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.854795 · Cited by 16
A bibliometrics and visualization analysis of cannabidiol research from 2004 to 2021
Liu, L., Liu, J., Zhao, M., Cai, M., Lei, F., Zeng, X., & Zhu, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.969883 · Cited by 17
State of the Art Antiemetic Therapy for Cancer Patients
Lau, T. K. H., Yip, C. H. W., & Yeo, W. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0486-5 · Cited by 16
Pain medication and long QT syndrome
Klivinyi, C., & Bornemann‐Cimenti, H. (2018) · The Korean journal of pain · doi:10.3344/kjp.2018.31.1.3 · Cited by 16
Novel Approaches for Treating Pain in Children
Splinter, W. M. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0766-6 · Cited by 16
Nabilone administration in refractory chronic diarrhea: a case series
Pellesi, L., Verga, M. C., Maria, N. D., Villa, E., Pini, L. A., & Guérzoni, S. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1024-y · Cited by 16
Cannabis: are there any benefits?
Vickery, A. W., & Finch, P. M. (2020) · Internal Medicine Journal · doi:10.1111/imj.15052 · Cited by 21
Blázquez, C., Ruiz-Calvo, A., Bajo‐Grañeras, R., Baufreton, J., Resel, E., Varilh, M., Zottola, A. C. P., Mariani, Y., Cannich, A., Rodríguez‐Navarro, J. A., et al. (2020) · eLife · doi:10.7554/elife.56811 · Cited by 15
Rodrigues, V. H., de Melo, M. M. R., Tenberg, V., Carreira, R., Portugal, I., & Silva, C. M. (2021) · Industrial Crops and Products · doi:10.1016/j.indcrop.2021.113339 · Cited by 15
Íñiguez-Luna, M. I., Cadena-Íñiguez, J., Soto‐Hernández, M., Flores, F. J. M., Cortés-Cruz, M., Watanabe, K. N., Machida-Hirano, R., & Cadena-Zamudio, J. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-85676-7 · Cited by 15
Carrell, D., Cronkite, D., Shea, M. A., Oliver, M. M., Luce, C., Matson, T. E., Bobb, J. F., Hsu, C. W., Binswanger, I. A., Browne, K. C., et al. (2022) · Substance Abuse · doi:10.1080/08897077.2021.1986767 · Cited by 15
Cannabis for the treatment of ulcerative colitis
Kafil, T. S., Nguyen, T. M., MacDonald, J. K., & Chande, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012954 · Cited by 15
Giossi, R., Carrara, F., Padroni, M., Bilancio, M. C., Mazzari, M., Enisci, S., Romio, M. S., Boni, G., Corrù, F., Fittipaldo, V. A., et al. (2022) · Pain and Therapy · doi:10.1007/s40122-022-00434-5 · Cited by 15
Collins, A. B., Beaudoin, F. L., Metrik, J., & Wightman, R. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109853 · Cited by 15
Watson, C. W., Sundermann, E. E., Helm, J. L., Paolillo, E. W., Hong, S., Ellis, R. J., Letendre, S. L., Marcotte, T. D., Heaton, R. K., Morgan, E. E., et al. (2023) · AIDS and Behavior · doi:10.1007/s10461-023-04056-6 · Cited by 15
Wiciński, M., Fajkiel-Madajczyk, A., Kurant, Z., Gryczka, K., Kurant, D., Szambelan, M., Malinowski, B., Falkowski, M., Zabrzyński, J., & Słupski, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144620 · Cited by 19
Kleiner, D., Horváth, I. L., Bunduc, Ș., Gergő, D., Lugosi, K., Fehérvári, P., Hegyi, P., & Csupor, D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230727094431 · Cited by 16
Sofrás, F. M. S., Alonso, R., Retta, D., Lira, P. D. L., Desimone, M. F., & van Baren, C. M. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230809094304 · Cited by 16
Safety and risks of CBD oils purchased online: unveiling uncertain quality and vague health claims
Vida, R. G., Strauss, L. V., Bajtel, Á., Kiss, T., Csupor, D., & Fittler, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1273540 · Cited by 15
Oihabi, M. E., Soultana, M., Ammari, M., Allal, L. B., & Lanjri, A. F. (2024) · Case Studies in Chemical and Environmental Engineering · doi:10.1016/j.cscee.2024.100732 · Cited by 16
Cannabinoids Used for Medical Purposes in Children and Adolescents
Chhabra, M., Ben‐Eltriki, M., Mansell, H., Lê, M., Huntsman, R. J., Finkelstein, Y., & Kelly, L. E. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.3045 · Cited by 19
Medical Marijuana: Just the Beginning of a Long, Strange Trip?
Ciccone, C. D. (2016) · Physical Therapy · doi:10.2522/ptj.20160367 · Cited by 15
Postoperative Shivering Among Cannabis Users at a Public Hospital in Trinidad, West Indies
Sankar-Maharaj, S., Chen, D., & Hariharan, S. (2017) · Journal of PeriAnesthesia Nursing · doi:10.1016/j.jopan.2016.03.010 · Cited by 15
Pain Management for Primary Care Providers: A Narrative Review of High-Impact Studies, 2014–2016
Becker, W. C., Bair, M. J., Picchioni, M., Starrels, J. L., & Frank, J. W. (2017) · Pain Medicine · doi:10.1093/pm/pnx146 · Cited by 15
Bruce, D., Bouris, A. M., Bowers, S., Blocker, O., Lee, S., Glidden, M., Schneider, J. A., & Reirden, D. H. (2019) · Addiction Research & Theory · doi:10.1080/16066359.2019.1629427 · Cited by 17
Curtis, S. A., Lew, D., Spodick, J., Hendrickson, J. E., Minniti, C. P., & Roberts, J. D. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002325 · Cited by 15
Care of the Patient Using Cannabis
Williams, A. R., & Hill, K. P. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202011030 · Cited by 14
Merone, G. M., Tartaglia, A., Rossi, S., Santavenere, F., Bassotti, E., D’Ovidio, C., Bonelli, M., Rosato, E., de Grazia, U., Zanardo, A., et al. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114174 · Cited by 15
Swinton, M. K., Sundermann, E. E., Pedersen, L., Nguyen, J. D., Grelotti, D. J., Taffe, M. A., Iudicello, J. E., & Fields, J. A. (2021) · Viruses · doi:10.3390/v13091742 · Cited by 15
Hansen, J. S., Hansen, R. M., Petersen, T., Gustavsen, S., Oturai, A. B., Sellebjerg, F. T., Sædder, E. A., Kasch, H., Rasmussen, P. V., Finnerup, N. B., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11091212 · Cited by 15
Metadata
- Authors
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J.
- Affiliations
- University Hospitals Bristol NHS Foundation Trust (GB)
- Kleijnen Systematic Reviews (United Kingdom) (GB)
- Department of Medical, Oral, and Biotechnological Sciences, University “G. D'Annunzio” of Chieti-Pescara, Chieti, Italy5Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
- Medical School, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru7Health Outcomes and Clinical Epidemiology Section, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
- Radboud University Medical Center (NL)
- Institut für Epidemiologie und kongenitale Erkrankungen, Cepicon GmbH, Hamburg, Germany
- Maastricht University (NL)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-23
- Volume
- 313
- Issue
- 24
- Pages
- 2456
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120227293
- Semantic Scholar
- 029bce497e0633eb2a7895cfd3b315f9c462dd5f
- Cited by
- 2,169
- References
- 137
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 168 · 2023: 200 · 2022: 220 · 2021: 262 · 2020: 272 · 2019: 230 · 2018: 209 · 2017: 159 · 2016: 131 · 2015: 33
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- cannabinoids, medical cannabis, nausea and vomiting, chemotherapy-induced nausea, chronic pain, spasticity, multiple sclerosis, depression, anxiety, sleep disorders, psychosis, glaucoma, Tourette syndrome, adverse events, quality of life, activities of daily living, risk of bias, placebo comparison
- MeSH terms
- Anorexia, Mental Disorders, Cannabinoids, Tourette Syndrome, Glaucoma, Humans, Muscle Spasticity, Nausea, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
